Brand Revitalisation

This oral drop is used to protect the thyroid during radiological investigations requiring iodine dyes. Its use is uncommon but when needed, essential. Its supply across Europe was threatened due to a lack of high quality active ingredient suppliers. After acquisition of the product, Universal Medicines invested in the re-development of the active ingredient, so that supply of this medicine would be safeguarded for decades to come. It is expected that over 1 million patients will benefit from these efforts over the next decade.

Dimenhydrinate suppositories are used in patients that are too sick to take medicines orally. This is a rare but important clinical scenario, and due to its low demand many pharmaceutical companies have discontinued supply over the past few decades. Universal Medicines acquired the product, improved supply terms to safeguard access for its patients, and is now establishing access to this medicine to other territories where the product has been strongly demanded by doctors. It is expected that over 1.1 million patients will benefit from these efforts over the next decade.

Lypsyl lip balm is the oldest lip salve brand in continuous supply in British history. With a notable history of being the lip salve that took the first western explorers to Mount Everest, it has over the past two decades declined in favour over newer / fast fashion lip salves. Universal Medicines acquired the brand, believing in its simple and effective formulation being one that has withstood the test of time. Revitalising the brand through upgrading its manufacturing lines to improve product quality and supply flow, this will ensure that customers can access this cherished brand with improved quality through more avenues over the coming years.

Intravenous sotalol is used in extremely rare arrhythmia conditions under sub-specialist cardiology expert supervision. Due to its very low demands, this product was slowly withdrawn by pharmaceutical companies over the decades, threatening its future availability across Europe. Universal Medicines acquired the last remaining Marketing Authorisation in Europe, upgrading its manufacturing process, and re-launching the product in 2025, to ensure that this small but ultra-important product stays available for as long as cardiologists find a need for it. It is estimated that these efforts could have an adjunctive role to play in saving 30,000 lives over the next decade.